Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...

After having removed Zepbound from its shortage list in December ... compounded drugs and generic versions of an older Novo Nordisk medicine. Citi analyst Daniel Grosslight said he is less ...

Novo Nordisk’s Ozempic and Lilly’s Mounjaro treat Type 2 diabetes, while Wegovy and Zepbound are anti-obesity medications. The FDA has long warned that compounded medications, which it doesn ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE ... The higher efficacy of Eli Lilly’s Mounjaro and Zepbound is the reason why NVO has been losing market share. Both companies are ...

Zepbound's biggest rival was Novo Nordisk and its semaglutide-based products Wegovy and Ozempic. While Novo and Lilly still dominate the branded GLP-1 drug market, both drugmakers have been ...

(Reuters) -Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more ... compounding pharmacies and rival Novo Nordisk. The move comes as the competitive ...

While Novo Nordisk stock is less risky now due to its lower valuation, there are still risks. The company faces intense competition from Eli Lilly's Zepbound, which has shown promising results (20 ...

The Danish drugmaker Novo Nordisk said it has invested $6.5 billion ... sold under the brand names Mounjaro and Zepbound, was no longer in short supply. That meant pharmacies had to discontinue ...

(Reuters) -Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range of doses sold online to try to stave off competition from ...